← Leaderboards
Shibo Jiang
New York Blood Center
$8,062,102
Attributed
$13,077,412
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2006–18$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$16,753,078 · 8
By mechanism
R01$10,815,914 · 3
U19$3,675,666 · 2
U01$1,949,322 · 1
R21$312,176 · 1
P01$0 · 1
Top collaborators
- Maria Elena Bottazzi7 shared
- Peter J Hotez7 shared
- Sara Lustigman3 shared
Most similar at New York Blood Center
Same institution · by research overlap
- Sara Lustigman$21,771,096
- Lanying Du$16,789,459
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseClinical TrialsStructureProductionInfectionBinding (Molecular Function)Neutralizing AntibodyReceptor BindingVaccinesImmune ResponseDisease OutbreaksIn VivoPathogenAdjuvantAluminum SulfateProteinsAnimalsImmunizationResponseViralCellsLeadPreventPre-Clinical
Grant awards (30)
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$569,174
U01 · FY2018 · AI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$784,531
U01 · FY2017 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,165,855
R01 · FY2016 · AI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$595,617
U01 · FY2016 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,165,726
R01 · FY2015 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,134,359
R01 · FY2014 · AI
RBD recombinant protein-based SARS vaccine for biodefense$3,936
R01 · FY2014 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,085,321
R01 · FY2013 · AI
RBD recombinant protein-based SARS vaccine for biodefense$3,936
R01 · FY2013 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,501,840
R01 · FY2012 · AI
Rational Design of HIV Fusion Inhibitors Targeting gp41$366,601
R01 · FY2010 · AI · contact PI
SARS-CoV S Protein Receptor-binding Domain-based Vaccines$358,864
R01 · FY2010 · AI · contact PI
Rational Design of HIV Fusion Inhibitors Targeting gp41$251,759
R01 · FY2010 · AI · contact PI
Rational Design of HIV Fusion Inhibitors Targeting gp41$370,304
R01 · FY2009 · AI · contact PI
SARS-CoV S Protein Receptor-binding Domain-based Vaccines$362,489
R01 · FY2009 · AI · contact PI
Anti-HIV-1 Composite Cellulose Acetate Phthalate Film$1,057,967
U19 · FY2008 · AI · contact PI
Rational Design of HIV Fusion Inhibitors Targeting gp41$370,304
R01 · FY2008 · AI · contact PI
SARS-CoV S Protein Receptor-binding Domain-based Vaccines$362,489
R01 · FY2008 · AI · contact PI
Anti-HIV-1 Composite Cellulose Acetate Phthalate Film$1,283,308
U19 · FY2007 · AI · contact PI
Rational Design of HIV Fusion Inhibitors Targeting gp41$377,476
R01 · FY2007 · AI · contact PI
SARS-CoV S Protein Receptor-binding Domain-based Vaccines$370,061
R01 · FY2007 · AI · contact PI
Anti-HIV-1 Composite Cellulose Acetate Phthalate Film$1,334,391
U19 · FY2006 · HD · contact PI
Rational Design of HIV Fusion Inhibitors Targeting gp41$403,250
R01 · FY2006 · AI · contact PI
Rational Design of HIV Fusion Inhibitors Targeting gp41$312,176
R21 · FY2004 · AI
RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 CORE$290,336
R01 · FY2003 · AI
RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 CORE$290,336
R01 · FY2002 · AI
IN VITRO ANTI-HIV1 CAP ACTIVITY$0
P01 · FY2002 · HD
RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 CORE$290,336
R01 · FY2001 · AI
IN VITRO ANTI-HIV1 CAP ACTIVITY$0
P01 · FY2001 · HD
RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 CORE$290,336
R01 · FY2000 · AI